Getting Under the Skin: Targeting Cutaneous Autoimmune Disease.

Area of Science:

• Immunology
• Dermatology
• Autoimmunity

Background:

• Autoimmune skin diseases arise from immune system dysregulation, specifically an imbalance between effector and regulatory arms.
• Disruption of immune homeostasis leads to the immune system attacking healthy skin tissues.

Purpose of the Study:

• To review current and emerging therapeutic strategies for cutaneous autoimmune diseases.
• To provide a framework for understanding the distinct mechanisms of action for these therapies.

Main Methods:

• Discussion of current therapies targeting the effector arm, including cytokine blockade, cellular depletion, intracellular signaling blockade, and costimulatory blockade.
• Exploration of emerging strategies targeting the regulatory arm, such as regulatory T cell therapy, chimeric autoantibody receptor T cells, low-dose interleukin-2, immune checkpoint stimulation, tolerogenic vaccines, and microbiome biotherapy.

Main Results:

• Targeting the effector arm has shown increased treatment efficacy compared to broad immunosuppressants.
• Emerging strategies targeting the regulatory arm offer potential for inducing tolerance and disease remission.

Conclusions:

• While targeting the effector arm has advanced treatment, new strategies are needed for diseases lacking clear pathways.
• Therapies aimed at restoring immune homeostasis by modulating the regulatory arm represent a promising frontier for treating cutaneous autoimmunity.